Navigation Links
Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
Date:11/11/2008

Genetic Variations Identify Predisposition and Risks of Progression of Vertebral Fracture in US-Caucasian Women

WALTHAM, Mass., Nov. 11 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), announced today that Nazneen Aziz, Ph.D., the company's Vice President of Research and Development, will present new research findings on the genetics of osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics, which takes place from Nov. 11-15, 2008, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Dr. Aziz will present poster #2146 on Nov. 13, at the poster session from 4:30 to 6:00 p.m. in Exhibit Hall C.

The title of the presentation is "Association of vertebral fracture with vertebral fracture with Interleukin gene polymorphisms in a large case-control study" highlighting new findings on genetic predisposition risk factors in Caucasian women for vertebral fractures. This study is a collaboration with the Study of Osteoporotic Fracture (SOF), multi-center study on osteoporosis and aging in women greater than or equal to age 65. In addition to adjudication of fractures, SOF has tracked cases of incident breast cancer, stroke, and total and cause-specific mortality. The data include serial measures of bone mineral density, measurements of sex and calcitropic hormones, tests of strength and function, cognitive exams, use of medication, health habits and much more. In 1986, SOF enrolled 9,704 primarily Caucasian women and continues to track these women with clinical visits every two years.

Dr. Aziz commented, "This information should be valuable in guiding the medical management of high-risk patients and in smarter design of clinical trial for the enrollment of patients who are at risk for vertebral fractures in trials of investigational new drugs."

About Osteoporosis

According to the National Osteoporosis Foundation Osteoporosis is a disease in which bones become fragile and more likely to break. If not prevented or if left untreated, osteoporosis can progress painlessly until a bone breaks. These broken bones, also known as fractures, occur typically in the hip, spine, and wrist. Any bone can be affected, but of special concern are fractures of the hip and spine. A hip fracture almost always requires hospitalization and major surgery. It can impair a person's ability to walk unassisted and may cause prolonged or permanent disability or even death. Spinal or vertebral fractures also have serious consequences, including loss of height, severe back pain, and deformity. Approximately eight million US women are estimated to have osteoporosis and 22 million are at risk of the disease. While women are four times more likely than men to develop the disease, men also suffer from osteoporosis.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
8. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
9. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
10. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the second quarter of 2016. The cash ... about July 29, 2016 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:5/22/2016)... Raleigh, NC (PRWEB) , ... May 22, 2016 , ... ... powerful weapons in combating the asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted ... , Researchers in the University of Rome’s Department of Clinical Sciences and Translational Medicine ...
(Date:5/19/2016)... Virginia (PRWEB) , ... May 19, 2016 , ... Anton ... new 30,000 square foot office building is complete. The new structure adds a third ... 2011, Anton Paar USA purchased 2.4 acres of land, along with office ...
(Date:5/19/2016)... MADRID , May 19, 2016 ... di una sessione orale durante il 52 ° ... (abstract n. 8006)    - Le conclusioni ... quanto riguarda i pazienti trattati, di cui il 90% presenta ... di sei mesi o più. Il settantadue per cento dei ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):